nach oben

Erschienen in:

04.02.2022 | Regenerative Pain Medicine/Interventional Pain Medicine (EC Bradley, Section Editors)

Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data

verfasst von: Charles A. Odonkor, Tariq AlFarra, Peju Adekoya, Vwaire Orhurhu, Tomás Rodríguez, Emily Sottosanti, Alan D. Kaye

Erschienen in: Current Pain and Headache Reports | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The main objective of this review is to appraise the literature on the role of spinal cord stimulation (SCS), cannabinoid therapy, as well as SCS and cannabinoid combination therapy for the management of chronic neuropathic and nociceptive pain. Current research suggests that SCS reduces pain and increases functional status in carefully selected patients with minimal side effects.

Recent Findings

As cannabinoid-based medications become a topic of increasing interest in pain management, data remains limited regarding the clinical efficacy of cannabinoids for pain relief. Furthermore, from a mechanistic perspective, although various pain treatment modalities utilize overlapping pain-signaling pathways, clarifying whether cannabinoids work synergistically with SCS via shared mechanisms remains to be determined. In considering secondary outcomes, the current literature suggests cannabinoids improve quality of life, specifically sleep quality, and that SCS decreases opioid consumption, increases functional capacity, and decreases long-term healthcare costs.

Summary

These findings, along with the high safety profiles of SCS and cannabinoids overall, incentivize further exploration of cannabinoids as an adjunctive therapy to SCS in the treatment of neuropathic and nociceptive pain.

Nur mit Berechtigung zugänglich

•• Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington (DC): National Academies Press (US). 2011. PMID: 22553896. Addresses the current state of pain research, care, and education; and provides recommendations intended to improve pain management approaches.

•• Park PW, Dryer RD, Hegeman-Dingle R, Mardekian J, Zlateva G, Wolff GG, et al. Cost burden of chronic pain patients in a large integrated delivery system in the United States. Pain Pract [Internet]. 1 Nov 2016. 2019;16(8):1001–11. Available from: https://doi.org/10.1111/papr.12357. Estimates healthcare costs and resource utilization among chronic pain patients. Results support using integrated delivery systems to evaluate ways to improve outcomes and lower healthcare costs for chronic pain patients.

• Jackson T, Thomas S, Stabile V, Han X, Shotwell M, McQueen K. Prevalence of chronic pain in low-income and middle-income countries: a systematic review and meta-analysis. Lancet [Internet]. 2015 Apr 27 [cited 2019 Jan 5]; 385: S10. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60805-4/fulltext. Meta-analysis of the range and prevalence of chronic pain in low-income and middle-income countries in anticipation of emergency and essential surgery services continuing to develop in these countries.

•• Rice ASC, Smith BH, Blyth FM. Pain and the global burden of disease. Pain [Internet]. 2016 Apr [cited 2019 Jan 5];157(4):791–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006396-201604000-00006 . Article analyzing The Global Burden of Disease (GBD) Study of 2013, a comprehensive and extensive assessment of the global burden of chronic pain down to the country level over a 23-year time period.

Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology [Internet]. 1990 Apr [cited 2019 Jan 5];72(4):711–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2157353

Dubin AE, Patapoutian A. Nociceptors: the sensors of the pain pathway. J Clin Invest [Internet]. 2010 Nov [cited 2019 Jan 5];120(11):3760–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21041958

Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature [Internet]. 2001 Sep 13 [cited 2019 Jan 5];413(6852):203–10. Available from: http://www.nature.com/doifinder/10.1038/35093019

• Lumpkin EA, Caterina MJ. Mechanisms of sensory transduction in the skin. Nature [Internet]. 2007 Feb 22 [cited 2019 Jan 5];445(7130):858–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17314972. Describes the complexity of the skin's sensory functions and their involvement with various signaling molecules and cell types in an attempt to better understand underlying somatosensation.

Baliki MN, Apkarian AV. Nociception, pain, negative moods, and behavior selection. Neuron [Internet]. 2015 Aug 5 [cited 2019 Jan 5];87(3):474–91. Available from: https://www.sciencedirect.com/science/article/pii/S0896627315005188

10.

Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci [Internet]. 2017 Jan 1 [cited 2019 Jan 5];18(1):20–30. Available from: http://www.nature.com/articles/nrn.2016.162

11.

Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron [Internet]. 2006 Oct 5 [cited 2019 Jan 7];52(1):77–92. Available from: https://www.sciencedirect.com/science/article/pii/S0896627306007288

12.

• Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology [Internet]. 2008 Apr 29 [cited 2019 Jan 7];70(18):1630–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18003941 . Proposes a grading system of definite, probable, and possible neuropathic pain for clinical and research purposes given the lack of specific diagnostic tools for neuropathic pain.

13.

Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, et al. Peripheral neuropathic pain. Pain [Internet]. 2017 Feb [cited 2019 Jan 7];158(2):261–72. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006396-201702000-00010

14.

Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc [Internet]. 2015 Apr 1 [cited 2019 Jan 5];90(4):532–45. Available from: https://www.sciencedirect.com/science/article/pii/S0025619615001056

15.

Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med [Internet]. 2017 Sep 5 [cited 2019 Jan 9];167(5):293. Available from: http://annals.org/article.aspx?doi=10.7326/M17-0865

16.

Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther [Internet]. 2017 Dec 24 [cited 2019 Jan 9];6(S1):25–33. Available from: http://link.springer.com/10.1007/s40122-017-0091-4

17.

Boom M, Niesters M, Sarton E, Aarts L, W Smith T, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des [Internet]. 2012 Dec 1 [ cited 2020 Jan 10];18(37):5994–6004. Available from: https://pubmed.ncbi.nlm.nih.gov/22747535/

18.

Fuchs PN, Roza C, Sora I, Uhl G, Raja SN. Characterization of mechanical withdrawal responses and effects of μ-, δ-and κ-opioid agonists in normal and μ-opioid receptor knockout mice. Brain Res [Internet]. 1999 Mar 13 [cited 2020 Jan 10];821(2):480–6. Available from: https://pubmed.ncbi.nlm.nih.gov/10064835/

19.

Nadal X, La Porta C, Bura SA, Maldonado R. Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol [Internet]. 2013 Sep 15 [cited 2020 Jan 10];716(1–3):142–57. Available from: https://pubmed.ncbi.nlm.nih.gov/23523475/

20.

Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther [Internet]. 2017 Dec 24 [cited 2019 Jan 10];6(S1):35–42. Available from: http://link.springer.com/10.1007/s40122-017-0087-0

21.

Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol [Internet]. 2015 Dec 18 [cited 2019 Jan 10];16(1):12. Available from: http://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-015-0150-5

22.

• Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α 2 δ -1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect [Internet]. 2016 Apr 1 [cited 2019 Jan 9];4(2):e00205. Available from: http://doi.wiley.com/10.1002/prp2.205. A review of the role of the α 2 δ-1 subunit and mechanisms of analgesic action and clinical efficacy of gabapentinoid drugs in response to relatively high number needed to treat for gabapentin and pregabalin across neuropathies.

23.

Moulin D, Boulanger A, Clark A, Clarke H, Dao T, Finley G, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag [Internet]. 2014 [cited 2019 Jan 10];19(6):328–35. Available from: http://www.hindawi.com/journals/prm/2014/754693/

24.

Porreca F, Tang Q, Bian D, Riedl M, Elde R, Lai J. Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res [Internet]. 1998 [cited 2019 Feb 10] 8;795(1–2):197–203. Available from: https://pubmed.ncbi.nlm.nih.gov/9622629/

25.

Dickenson AH, Matthews EA, Suzuki R. Central nervous system mechanisms of pain in peripheral neuropathy. Prog Pain Res Manag [Internet]. 2001[ cited 2020 Feb 10] 21; 85–106. Available from: https://pubmed.ncbi.nlm.nih.gov/10819088/

26.

Bell RF, Kalso EA. Ketamine for pain management. Pain Rep [Internet]. 2018 [ cited 2020 Feb 10] 3(5). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181464/

27.

Maher DP, Chen L, Mao J. Intravenous Ketamine Infusions for Neuropathic Pain Management. Anesth Analg [Internet]. 2017 Feb [cited 2019 Jan 9];124(2):661–74. Available from: https://insights.ovid.com/crossref?an=00000539-201702000-00041

28.

Fritzell P, Hägg O, Wessberg P, Nordwall A, Group SLSS, others. 2001 Volvo Award Winner in Clinical Studies: Lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group. Spine (Phila Pa 1976). 2001;26(23):2521–32.

29.

Fairbank J, Frost H, Wilson-MacDonald J, Yu L-M, Barker K, Collins R, et al. Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilisation trial. BMJ [Internet]. 2005 May 28 [cited 2019 Jan 12];330(7502):1233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15911537

30.

Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain. 2002;18(6):355–65.CrossRef

31.

Leggett LE, Soril LJ, Lorenzetti DL, Noseworthy T, Steadman R, Tiwana S, et al. Radiofrequency Ablation for Chronic Low Back Pain: A Systematic Review of Randomized Controlled Trials. Pain Res Manag [Internet]. 2014 [cited 2019 Jan 11];19(5):e146–53. Available from: http://www.hindawi.com/journals/prm/2014/834369/

32.

McCormick ZL, Marshall B, Walker J, McCarthy R, Walega DR. Long-Term function, pain and medication use outcomes of radiofrequency ablation for lumbar facet syndrome. Int J Anesth Anesthesiol [Internet]. 2015 [cited 2019 Jan 11];2(2). Available from: http://www.ncbi.nlm.nih.gov/pubmed/26005713

33.

McCormick ZL, Korn M, Reddy R, Marcolina A, Dayanim D, Mattie R, et al. Cooled radiofrequency ablation of the genicular nerves for chronic pain due to knee osteoarthritis: six-month outcomes. Pain Med [Internet]. 2017 Sep 1 [cited 2019 Jan 11];18(9):1631–41. Available from: http://academic.oup.com/painmedicine/article/18/9/1631/3742154/Cooled-Radiofrequency-Ablation-of-the-Genicular

34.

Moens M, Goudman L, Brouns R, Valenzuela Espinoza A, De Jaeger M, Huysmans E, et al. Return to work of patients treated with spinal cord stimulation for chronic pain: a systematic review and meta-analysis. Neuromodulation Technol Neural Interface [Internet]. 2018 Aug 17 [cited 2019 Jan 13]. Available from: http://doi.wiley.com/10.1111/ner.12797

35.

Verrills P, Sinclair C, Barnard A. A review of spinal cord stimulation systems for chronic pain. J Pain Res [Internet]. 2016 [cited 2019 Jan 13]; 9:481–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27445503

36.

Atkinson L, Sundaraj SR, Brooker C, O’Callaghan J, Teddy P, Salmon J, et al. Recommendations for patient selection in spinal cord stimulation. J Clin Neurosci [Internet]. 2011 Oct 1 [cited 2019 Jan 13];18(10):1295–302. Available from: https://www.sciencedirect.com/science/article/pii/S0967586811002207

37.

Song JJ, Popescu A, Bell RL. Present and potential use of spinal cord stimulation to control chronic pain. Pain Physician [Internet]. [cited 2019 Jan 13];17(3):235–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24850105

38.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez A V., et al. Cannabinoids for Medical Use. JAMA [Internet]. 2015 Jun 23 [cited 2019 Jan 14];313(24):2456. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.6358

39.

Oakley JC, Prager JP. Spinal cord stimulation: mechanisms of action. Spine (Phila Pa 1976). 2002;27(22):2574–83.

40.

Pinzon EG, Killeffer JA. Spinal cord stimulation: fundamentals. Practical Pain Mgmt. [Internet]. 2013 [cited 2020 Jan 15];13:4. Available from: https://www.practicalpainmanagement.com/treatments/interventional/stimulators/spinal-cord-stimulation-fundamentals

41.

De Ridder D, Vancamp T, Vanneste S. Fundamentals of burst stimulation of the spinal cord and brain. InNeuromodulation 2018 Jan 1 (pp. 147–160). Academic Press.

42.

Guan Y. Spinal Cord Stimulation: Neurophysiological and Neurochemical Mechanisms of Action. Curr Pain Headache Rep [Internet]. 2012 Jun 8 [cited 2019 Jan 14];16(3):217–25. Available from: http://link.springer.com/10.1007/s11916-012-0260-4

43.

Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicenter randomized controlled trial in patients with failed back surgery syndrome. Pain [Internet]. 2007 Nov 1 [cited 2019 Jan 12];132(1–2):179–88. Available from: https://www.sciencedirect.com/science/article/pii/S0304395907004320

44.

van Beek M, Slangen R, Schaper NC, Faber CG, Joosten EA, Dirksen CD, et al. Sustained treatment effect of spinal cord stimulation in painful diabetic peripheral neuropathy: 24-month follow-up of a prospective two-center randomized controlled trial. Diabetes Care [Internet]. 2015 Sep 1 [cited 2019 Jan 14];38(9):e132–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26116722

45.

Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, et al. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain. Anesthesiology [Internet]. 2015 Oct 1 [cited 2019 Jan 14];123(4):851–60. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000542-201510000-00024

46.

Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, et al. Comparison of 10-kHz high-frequency and traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain. Neurosurgery [Internet]. 2016 Nov 1 [cited 2019 Jan 14];79(5):667–77. Available from: https://academic.oup.com/neurosurgery/article-lookup/doi/10.1227/NEU.0000000000001418

47.

Deer T, Slavin KV, Amirdelfan K, North RB, Burton AW, Yearwood TL, Tavel E, Staats P, Falowski S, Pope J, Justiz R, Fabi AY, Taghva A, Paicius R, Houden T, Wilson D. Success Using Neuromodulation With BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation. 2018;21(1):56–66. https://doi.org/10.1111/ner.12698 . (Epub 2017 Sep 29 PMID: 28961366).CrossRefPubMed

48.

Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. In: Cannabinoids [Internet]. Berlin/Heidelberg: Springer-Verlag; 2005 [cited 2019 Jan 14]. p. 327–65. Available from: http://link.springer.com/10.1007/3-540-26573-2_11

49.

Pertwee RG. Pharmacological actions of cannabinoids. In: Cannabinoids [Internet]. Berlin/Heidelberg: Springer-Verlag; 2005 [cited 2019 Jan 14]. p. 1–51. Available from: http://link.springer.com/10.1007/3-540-26573-2_1

50.

Chow RM, Marascalchi B, Abrams WB, Peiris NA, Odonkor CA, Cohen SP. Driving Under the Influence of Cannabis. Anesth Analg [Internet]. 2018 Jun [cited 2019 Jan 1];1. Available from: http://insights.ovid.com/crossref?an=00000539-900000000-96658

51.

Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol [Internet]. 2016 Jan 2 [cited 2019 Jan 1];54(1):1–13. Available from: http://www.tandfonline.com/10.3109/15563650.2015.1110590

52.

Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo-controlled crossover trial. BMJ [Internet]. 2004 Jul 31 [cited 2019 Jan 1];329(7460):253. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15258006

53.

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology [Internet]. 2005 Sep 27 [cited 2019 Jan 14];65(6):812–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9040716

54.

Lynch M, Cesar-Rittenberg P, and AH-J of pain, 2014 undefined. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic. ElsevierSign in [Internet]. [cited 2019 Jan 1]; Available from: https://www.sciencedirect.com/science/article/pii/S0885392413002388

55.

Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain [Internet]. 2004 Dec 1 [cited 2019 Jan 1];112(3):299–306. Available from: https://www.sciencedirect.com/science/article/pii/S0304395904004415

56.

Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy. Diabetes Care [Internet]. 2010 Jan 1 [cited 2019 Jan 1];33(1):128–30. Available from: http://care.diabetesjournals.org/content/33/1/128.short

57.

Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ [Internet]. 2008 Jan 24 [cited 2019 Jan 1];336(7637):199–201. Available from: https://www.bmj.com/content/336/7637/199?grp=1&casa_token=_YMoH7DTROgAAAAA:X_ekR-hd1RL9U5CdOFpFHSAk-8NNnZRc_37eqfiOC2XimcCx6ENVArJh6JcCqDipcaeIMmBa67b8

58.

• Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain. Anesth Analg [Internet]. 2017 Nov [cited 2019 Jan 1];125(5):1638–52. Available from: http://insights.ovid.com/crossref?an=00000539-201711000-00032 . Discusses the analgesic efficacy of selective cannabinoids compared to conventional management or placebo for chronic NP given the lack of consensus on their role in the treatment of neuropathic pain (NP) and contradictory recommendations among guidelines from national and international pain societies.

59.

Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. PAIN® [Internet]. 2012 Oct 1 [cited 2019 Jan 1];153(10):2073–82. Available from: https://www.sciencedirect.com/science/article/pii/S0304395912004009

60.

Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med [Internet]. 2015 Jan 1 [cited 2019 Jan 1];16(1):149–59. Available from: https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/pme.12569

61.

Maher DP, Martins YC, Doshi T, Bicket M, Zhang K, Hanna G, et al. Neuropathic pain medication use does not alter outcomes of spinal cord stimulation for lower extremity pain. Neuromodulation Technol Neural Interface [Internet]. 2018 Jan 1 [cited 2019 Jan 1];21(1):106–13. Available from: http://doi.wiley.com/10.1111/ner.12697

62.

Schechtmann G, Lind G, Winter J, Meyerson BA, Linderoth B. Intrathecal clonidine and baclofen enhance the pain-relieving effect of spinal cord stimulation. Neurosurgery [Internet]. 2010 Jul 1 [cited 2019 Jan 14];67(1):173–81. Available from: https://academic.oup.com/neurosurgery/article/67/1/173/2556606

63.

Mondello E, Quattrone D, Cardia L, Bova G, Mallamace R, Barbagallo AA, et al. Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res [Internet]. 2018 [cited 2019 Jan 1];11:1761–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30233233

64.

North RB, Kumar K, Wallace MS, Henderson JM, Shipley J, Hernandez J, Mekel-Bobrov N, Jaax KN. Spinal cord stimulation versus re-operation in patients with failed back surgery syndrome: an international multicenter randomized controlled trial (EVIDENCE study). Neuromodulation. 2011 Jul-Aug;14(4):330–5; discussion 335–6. https://doi.org/10.1111/j.1525-1403.2011.00371.x. Epub 2011 Jul 7. PMID: 21992427.

65.

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999–1012.CrossRef

66.

Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56–61. https://doi.org/10.1080/00325481.2019.1685298. (Epub 2019 Nov 12 PMID: 31711352).CrossRefPubMed

67.

Odonkor CA, Orman S, Orhurhu V, Stone ME, Ahmed S. Spinal cord stimulation vs conventional therapies for the treatment of chronic low back and leg pain: a systematic review of health care resource utilization and outcomes in the last decade. Pain Med. 2019;20(12):2479–94.CrossRef

68.

Kemler MA, Barendse GA, van Kleef M, de Vet HC, Rijks CP, Furnée CA, van den Wildenberg FA. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. 2000;343(9):618–24. https://doi.org/10.1056/NEJM200008313430904 . (PMID: 10965008).CrossRefPubMed

69.

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984–97. https://doi.org/10.1007/s00415-012-6739-4 . (Epub 2012 Nov 21 PMID: 23180178).CrossRefPubMed

70.

• Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017 Jun 1; 2(1):160–166. https://doi.org/10.1089/can.2017.0012. PMID: 28861516; PMCID: PMC5569620. Review of clinical outcomes where cannabis is offered as a viable substitute for pain treatment and as a medication assisted treatment for opioid dependence.

Titel: Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data
verfasst von: Charles A. Odonkor
Tariq AlFarra
Peju Adekoya
Vwaire Orhurhu
Tomás Rodríguez
Emily Sottosanti
Alan D. Kaye
Publikationsdatum: 04.02.2022
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports / Ausgabe 2/2022
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-022-01008-y

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data